These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 1726358

  • 1. Single institutional experience with non-seminomatous germ cell tumours of the testis: local perspectives on a curable cancer.
    Rosenthal MA, Stuart-Harris RC, Tiver KW, Langlands AO, Kefford RF.
    Aust N Z J Med; 1991 Dec; 21(6):857-62. PubMed ID: 1726358
    [Abstract] [Full Text] [Related]

  • 2. Germ cell tumours of testis: prognostic factors and results.
    Nikzas D, Champion AE, Fox M.
    Eur Urol; 1990 Dec; 18(4):242-7. PubMed ID: 1705226
    [Abstract] [Full Text] [Related]

  • 3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
    Aparicio J, Sánchez-Muñoz A, Ochenduszko S, Gumà J, Fernández-Aramburo A, García Del Muro X, Quiroga V, Sastre J, Alonso-Gordoa T, Sagastibelza N, Maroto P, Gómez de Liaño A, Vázquez S, Diz P, Durán I, Domenech M, Pinto A, Hernández A, González-Billalabeitia E, Terrasa J.
    J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
    [Abstract] [Full Text] [Related]

  • 6. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
    Swanson DA.
    Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
    [No Abstract] [Full Text] [Related]

  • 7. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M, Tryakin A, Kanagavel D, Bulanov A, Burova A, Figurin K, Fainshtein I, Sergeev U, Zakharova T, Garin A, Tjulandin S.
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.
    Lancet; 1985 Jan 05; 1(8419):8-11. PubMed ID: 2578205
    [Abstract] [Full Text] [Related]

  • 9. Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis.
    Raghavan D, Peckham MJ, Heyderman E, Tobias JS, Austin DE.
    Br J Cancer; 1982 Feb 05; 45(2):167-73. PubMed ID: 6174137
    [Abstract] [Full Text] [Related]

  • 10. [Clinical presentation of testicular germinal cancer].
    Fernández Gómez JM, Guate Ortiz JL, Martín Huescar A, Fresno Forcelledo F, Escaf Barmadah S, García Rodríguez J, Pérez García FJ, Rodríguez Faba O, Jalón Monzón A.
    Arch Esp Urol; 2002 Oct 05; 55(8):915-22. PubMed ID: 12455282
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration.
    Kildahl-Andersen A, Erke MG, Sagstuen H, Bremnes RM.
    Acta Oncol; 2005 Oct 05; 44(6):537-44. PubMed ID: 16165912
    [Abstract] [Full Text] [Related]

  • 13. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
    Gerl A, Clemm C, Lamerz R, Mann K, Wilmanns W.
    Eur J Cancer; 1993 Oct 05; 29A(7):961-5. PubMed ID: 7684597
    [Abstract] [Full Text] [Related]

  • 14. Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined.
    Raghavan D, Colls B, Levi J, Fitzharris B, Tattersall MH, Atkinson C, Woods R, Coorey G, Farrell C, Wines R.
    Br J Urol; 1988 Jun 05; 61(6):522-6. PubMed ID: 2840997
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective.
    Skinner DG, Scardino PT.
    J Urol; 1980 Mar 05; 123(3):378-82. PubMed ID: 6153725
    [Abstract] [Full Text] [Related]

  • 17. Active surveillance for stage I non-seminomatous germ cell testis tumors: practice and pitfalls.
    Raghavan D, Boyer M.
    Prog Clin Biol Res; 1990 Mar 05; 350():309-18. PubMed ID: 2166960
    [No Abstract] [Full Text] [Related]

  • 18. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin.
    Fottner C, Sattarova S, Hoffmann K, Spöttl G, Weber MM.
    Eur J Endocrinol; 2008 Sep 05; 159(3):317-27. PubMed ID: 18524796
    [Abstract] [Full Text] [Related]

  • 19. Surgery in infants and children with testicular and paratesticular tumours: a single centre experience over a 25-year-period.
    Tröbs RB, Krauss M, Geyer C, Tannapfel A, Körholz D, Hirsch W.
    Klin Padiatr; 2007 Sep 05; 219(3):146-51. PubMed ID: 17525908
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.